CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer
Abstract Cell cycle-dependent protein kinase 12 (CDK12) plays a key role in a variety of carcinogenesis processes and represents a promising therapeutic target for cancer treatment. However, to date, there have been no systematic studies addressing its diagnostic, prognostic and immunological value...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-56831-7 |
| _version_ | 1797247343509110784 |
|---|---|
| author | Ke-Qi Lu Zuo-Lin Li Qian Zhang Qing Yin Yi-Lin Zhang Wei-Jie Ni LiangYun-Zi Jiang Wei He Bin Wang |
| author_facet | Ke-Qi Lu Zuo-Lin Li Qian Zhang Qing Yin Yi-Lin Zhang Wei-Jie Ni LiangYun-Zi Jiang Wei He Bin Wang |
| author_sort | Ke-Qi Lu |
| collection | DOAJ |
| description | Abstract Cell cycle-dependent protein kinase 12 (CDK12) plays a key role in a variety of carcinogenesis processes and represents a promising therapeutic target for cancer treatment. However, to date, there have been no systematic studies addressing its diagnostic, prognostic and immunological value across cancers. Here, we found that CDK12 was significantly upregulated in various types of cancers, and it expression increased with progression in ten cancer types, including breast cancer, cholangiocarcinoma and colon adenocarcinoma. Moreover, the ROC curves indicated that CDK12 showed diagnostic value in eight cancer types. High CDK12 expression was associated with poor prognosis in eight types of cancer, including low-grade glioma, mesothelioma, melanoma and pancreatic cancer. Furthermore, we conducted immunoassays to explore the exact mechanisms underlying CDK12-induced carcinogenesis, which revealed that increased expression of CDK12 allowed tumours to evade immune surveillance and upregulate immune checkpoint genes. Additionally, mutational studies have shown that amplification and missense mutations are the predominant mutational events affecting CDK12 across cancers. These findings establish CDK12 as a significant biological indicator of cancer diagnosis, prognosis, and immunotherapeutic targeting. Early surveillance and employment of CDK12 inhibitors, along with concomitant immunotherapy interventions, may enhance the clinical outcomes of cancer patients. |
| first_indexed | 2024-04-24T19:57:11Z |
| format | Article |
| id | doaj.art-825f18d63ec94122a1d78db9691bc801 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T19:57:11Z |
| publishDate | 2024-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-825f18d63ec94122a1d78db9691bc8012024-03-24T12:15:42ZengNature PortfolioScientific Reports2045-23222024-03-0114111710.1038/s41598-024-56831-7CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancerKe-Qi Lu0Zuo-Lin Li1Qian Zhang2Qing Yin3Yi-Lin Zhang4Wei-Jie Ni5LiangYun-Zi Jiang6Wei He7Bin Wang8Institute of Nephrology, Zhong Da Hospital, Southeast University School of MedicineInstitute of Nephrology, Zhong Da Hospital, Southeast University School of MedicinePediatric Surgery, The First Affiliated Hospital of Zhengzhou UniversityInstitute of Nephrology, Zhong Da Hospital, Southeast University School of MedicineInstitute of Nephrology, Zhong Da Hospital, Southeast University School of MedicineInstitute of Nephrology, Zhong Da Hospital, Southeast University School of MedicineInstitute of Nephrology, Zhong Da Hospital, Southeast University School of MedicineDepartment of Gastroenterology, Jiangsu Province Geriatric Institute, and Jiangsu Province Official Hospital, Geriatric Hospital of Nanjing Medical UniversityInstitute of Nephrology, Zhong Da Hospital, Southeast University School of MedicineAbstract Cell cycle-dependent protein kinase 12 (CDK12) plays a key role in a variety of carcinogenesis processes and represents a promising therapeutic target for cancer treatment. However, to date, there have been no systematic studies addressing its diagnostic, prognostic and immunological value across cancers. Here, we found that CDK12 was significantly upregulated in various types of cancers, and it expression increased with progression in ten cancer types, including breast cancer, cholangiocarcinoma and colon adenocarcinoma. Moreover, the ROC curves indicated that CDK12 showed diagnostic value in eight cancer types. High CDK12 expression was associated with poor prognosis in eight types of cancer, including low-grade glioma, mesothelioma, melanoma and pancreatic cancer. Furthermore, we conducted immunoassays to explore the exact mechanisms underlying CDK12-induced carcinogenesis, which revealed that increased expression of CDK12 allowed tumours to evade immune surveillance and upregulate immune checkpoint genes. Additionally, mutational studies have shown that amplification and missense mutations are the predominant mutational events affecting CDK12 across cancers. These findings establish CDK12 as a significant biological indicator of cancer diagnosis, prognosis, and immunotherapeutic targeting. Early surveillance and employment of CDK12 inhibitors, along with concomitant immunotherapy interventions, may enhance the clinical outcomes of cancer patients.https://doi.org/10.1038/s41598-024-56831-7CDK12Pan-cancerDiagnosisPrognosisImmunizationGene mutation |
| spellingShingle | Ke-Qi Lu Zuo-Lin Li Qian Zhang Qing Yin Yi-Lin Zhang Wei-Jie Ni LiangYun-Zi Jiang Wei He Bin Wang CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer Scientific Reports CDK12 Pan-cancer Diagnosis Prognosis Immunization Gene mutation |
| title | CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer |
| title_full | CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer |
| title_fullStr | CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer |
| title_full_unstemmed | CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer |
| title_short | CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer |
| title_sort | cdk12 is a potential biomarker for diagnosis prognosis and immunomodulation in pan cancer |
| topic | CDK12 Pan-cancer Diagnosis Prognosis Immunization Gene mutation |
| url | https://doi.org/10.1038/s41598-024-56831-7 |
| work_keys_str_mv | AT keqilu cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT zuolinli cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT qianzhang cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT qingyin cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT yilinzhang cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT weijieni cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT liangyunzijiang cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT weihe cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer AT binwang cdk12isapotentialbiomarkerfordiagnosisprognosisandimmunomodulationinpancancer |